Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).

ABSTRACT:

Introduction

We aimed to assess if ranolazine would improve angina symptoms among patients with documented myocardial ischemia.

Methods

Eligible subjects had chronic stable angina and at least one coronary stenosis with fractional flow reserve (FFR) ≤0.80 or at least one chronic total occlusion (CTO) without attempted revascularization. Subjects were randomized to oral ranolazine 500 mg twice daily for 1 week, then ranolazine 1000 mg twice daily for 15 weeks versus matching placebo. The primary end point was change in angina at 16 weeks as assessed by the Seattle Angina Questionnaire (SAQ).

Results

Between September 2014 and January 2016, 25 subjects were randomized to ranolazine versus 25 to placebo. The most common reason for eligibility was CTO (72%), while the rem

SUBMITTER: Bavry AA 

PROVIDER: S-EPMC5446814 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature